Clinical trials
Glioblastoma clinical trials
Below are recruiting glioblastoma clinical trials, each written for real people, not researchers. We’re tracking 317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT06097975RecruitingPhase 1
Combined immunotherapy for recurrent glioblastoma
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
BrusselsAges 18 years+ - NCT06102525RecruitingPhase 1/Phase 2
Testing RZ-001 with valganciclovir for glioblastoma
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
IncheonAges 18 years+ - NCT06113705Recruiting
Better MRI and blood tests for glioblastoma treatment response
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
RozzanoAges 18 years+ - NCT06140875Recruiting
Radiofrequency treatment plus standard therapy for glioblastoma
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
BerlinAges 18–70 - NCT06160206RecruitingPhase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Scottsdale, ArizonaAges 18 years+ - NCT06183983Recruiting
Advanced MRI for better glioblastoma radiation
This trial tests whether using advanced MRI scans before radiation therapy can help doctors target the tumor more precisely and possibly improve outcomes for people with glioblastoma. It aims to make radiation treatment more personalized.
Rotterdam, South HollandAges 18 years+ - NCT06220552RecruitingPhase 2
Low-dose radiation plus immunotherapy for recurrent glioblastoma
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Zhuhai, GuangdongAges 18 years+ - NCT06222138Recruiting
Biomarker study of TTFields in newly diagnosed glioblastoma
This trial looks at how well Tumor Treating Fields (TTFields) therapy works for people with newly diagnosed glioblastoma. Researchers will study blood and tumor samples to find markers that might predict how well the treatment works.
ToulouseAges 18 years+ - NCT06271421Recruiting
Nanoparticle heat therapy for recurrent glioblastoma
This trial tests a new treatment for recurrent glioblastoma using tiny magnetic particles (nanoparticles) that are heated to kill cancer cells. The particles are injected into the tumor, and then a magnetic field device heats them up. It's for people who have already tried standard therapy and whose tumor has come back.
PoznanAges 18 years+ - NCT06297512RecruitingPhase 2
Testing chemotherapy after radiation for young patients with glioblastoma
This trial tests whether a type of chemotherapy called anthracycline can help young patients with glioblastoma when given after radiation therapy. It aims to see if this treatment improves outcomes for patients aged 3 to 30.
FlorenceAges 3–30 - NCT06327451RecruitingPhase 2
Atorvastatin plus temozolomide for EGFR-positive glioblastoma
This trial tests whether adding the cholesterol drug atorvastatin to the standard chemotherapy temozolomide improves outcomes for people with a specific type of glioblastoma (brain cancer) that is positive for the EGFR protein. It aims to find a more effective treatment for this aggressive tumor.
TianjinAges 18–60 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06356883RecruitingPhase 2
Two chemo combos for progressing glioblastoma
This trial tests two different combinations of chemotherapy drugs given directly into the artery that feeds the brain tumor. It is for people with glioblastoma (a type of brain tumor) that has continued to grow after standard treatment.
Sherbrooke, QuebecAges 18 years+ - NCT06385132Recruiting
Studying mental health in brain and head/neck cancer
This study looks at the emotional and mental health of people with glioblastoma (a type of brain tumor) or head and neck cancer who are getting a long course of radiation therapy. The goal is to understand how they are feeling so doctors can provide better support.
RomaAges 18–75 - NCT06389591RecruitingPhase 1
RNA Vaccine for Recurrent Glioblastoma
This trial tests a new personalized RNA vaccine made from your own tumor tissue. It is designed to help your immune system fight the cancer after it has returned. You will have surgery to collect the tumor, and then the vaccine is given to try to stop the tumor from growing again.
Gainesville, FloridaAges 18–80 - NCT06410248RecruitingPhase 1
Triapine and temozolomide for recurrent glioblastoma
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06466031Recruiting
PET/MRI for guiding glioblastoma surgery
This trial tests whether a special PET scan combined with MRI can help guide surgery for glioblastoma. It is for people with a newly diagnosed, single tumor who are candidates for surgery.
Lodz, Łódź VoivodeshipAges 18–70 - NCT06504381RecruitingPhase 1/Phase 2
DB107 and radiation therapy for high-grade glioma
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06512311Recruiting
Personalized drug testing for newly diagnosed glioblastoma
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
Vienna, State of ViennaAges 18–75 - NCT06533163Recruiting
Magnetic therapy for new glioblastoma
This trial tests a new low-intensity magnetic treatment (like a gentle magnetic pad placed on your head) for people with a newly diagnosed, aggressive brain tumor called glioblastoma. It aims to see if different amounts of exposure to this therapy are safe and help slow tumor growth.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06558214RecruitingPhase 2
Laser surgery, Optune device, and Keytruda for recurrent glioblastoma
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Gainesville, FloridaAges 18–90 - NCT06595186RecruitingPhase 2
JK-1201I plus temozolomide for newly diagnosed glioblastoma
This trial tests a new drug called JK-1201I combined with the standard chemotherapy temozolomide after you finish your initial radiation and chemo. It is for people with newly diagnosed glioblastoma who have had most of their tumor removed and are now ready for the next phase of treatment.
BeijingAges 18–75
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma?
- Yes. Clin2 currently lists 317 recruiting glioblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.